Kratom products, which have been sold in the U.S. for decades with minimal regulatory oversight, are increasingly being replaced by more potent semi-synthetic derivatives, particularly 7-hydroxymitragynine, known as 7-OH. These substances are commonly used to manage chronic pain, anxiety, and opioid withdrawal symptoms. While kratom’s main psychoactive compounds currently lack federal scheduling, concerns about potential physical dependence—particularly with highly concentrated 7-OH products—have prompted calls for regulatory action.
In July, the Drug Enforcement Administration proposed temporarily designating 7-OH above certain potency thresholds as Schedule I, the most restrictive drug classification. This approach would allow milder, natural kratom products to remain largely unregulated. However, experts voice significant concerns about this strategy, noting it could leave dependent users vulnerable to withdrawal symptoms and criminal prosecution while creating enforcement challenges as manufacturers develop new synthetic variants. The public comment period for the proposal ended with nearly 36,000 submissions, and the DEA has not yet finalized the regulation.
Alternative regulatory approaches are being tested at the state level. Utah and West Virginia have implemented more comprehensive marketplace oversight, requiring products to be tested by third-party laboratories, sold only through licensed retailers, and meeting specific labeling and safety standards. These states fund enforcement through product taxes. Around two dozen states have adopted some version of the Kratom Consumer Protection Act, though critics argue many versions lack sufficient consumer protections. Policymakers acknowledge that scheduling alone may not address the underlying conditions driving kratom use and that more robust marketplace regulation requires substantial resources for testing and enforcement.
Recent pressure for action increased following deaths of two University of Mississippi students, though authorities have not attributed these to kratom use. As synthetic derivatives continue to evolve, experts express concern that regulatory approaches may struggle to keep pace with emerging substances, potentially requiring broader legal language to capture kratom-related derivatives rather than individual compounds.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI